New investigational drug targets pancreatic cancer cells
September 16th, 2010 - 4:55 pm ICT by ANIWashington, Sep 16 (ANI): A patient at the Virginia G. Piper Cancer Center at Scottsdale Healthcare has been administered a new investigational drug designed to penetrate and attack pancreatic cancer cells.
ASG-5ME is a potent, targeted compound designed to selectively kill cancer cells, says Daniel Von Hoff, MD, a principal investigator in the Phase I clinical trial. Pancreatic cancer is a fast-growing and difficult to treat form of cancer, and is the fourth leading cause of cancer death in the United States.
“Our goal at the Virginia G. Piper Cancer Center is to deliver cell-killing medicine through the best possible individually targeted therapies, and ASG-5ME fits the bill,” says Von Hoff.
The new investigational compound uses a monoclonal antibody against a target which is found in more than 90 percent of pancreatic cancer patients. The monoclonal antibody delivers a highly potent molecule called monomethyl auristatin E (MMAE) to selectively kill the pancreatic cancer cells.
“It is a precision approach that is designed to avoid non-targeted cells, increasing antitumor activity in preclinical models and potentially reducing the toxic effects of traditional chemotherapy” says Dr. Von Hoff. Researchers are studying the drug to evaluate its safety and tolerability and identify the maximum tolerated dose.
The Virginia G. Piper Cancer Center at Scottsdale Healthcare was the first to offer patient access to ASG-5ME. Researchers hope to enroll up to 50 patients in clinical trials of the drug in multiple centers across the U.S. (ANI)
- Novel treatment gives hope to lymphoma, leukemia patients - Feb 27, 2010
- New targeted therapy delivers chemo directly to ovarian cancer cells - Jul 30, 2009
- Life work culminates in testing of cancer therapy in humans - Mar 24, 2011
- New drug that aims to 'seek and destroy' cancer identified - Oct 07, 2009
- New drug effective against breast tumours - Dec 13, 2009
- Novel immune therapy for pancreatic cancer discovered - Mar 25, 2011
- Revolutionary drug brings new hope for adrenal cancer patients - Sep 23, 2009
- Monoclonal antibodies can be used as potent immune weapons against cancer - Mar 22, 2009
- New drug shrinks cancer, with few side effects - Apr 07, 2011
- Targeted treatment for prostate cancer to be tested - Apr 17, 2010
- Synthetic compound may lead to drugs to fight pancreatic, lung cancer - Mar 10, 2011
- New therapy shows promising result for HER2-positive metastatic disease - Oct 09, 2010
- New myeloma drug shows promise - Jun 08, 2010
- Possible new treatment strategies for pancreatic cancer found - Mar 04, 2011
- New hope for cancer cure - Jul 08, 2011
Tags: cancer cells, cancer center, cancer death, cause of cancer, chemotherapy, clinical trial, drug targets, hoff, investigational compound, investigational drug, maximum tolerated dose, molecule, monoclonal antibody, pancreatic cancer patients, precision approach, principal investigator, scottsdale healthcare, target, toxic effects, traditional chemotherapy